

# Biomarker Integration in Ayurvedic Diagnosis

Andreas Nowak<sup>1</sup>, Pierre Muller<sup>2</sup>, Jonas Moreau<sup>3</sup>

<sup>1</sup> Assistant Professor, Institute of Intelligent Systems, Mediterranean Institute of Technology, Rome, Italy. Email: andreas.nowak506@gmail.com | ORCID: 3463-2866-5350-1473

<sup>2</sup> Research Scientist, Department of Machine Learning, Swiss Institute of Machine Intelligence, Zurich, Switzerland. Email: pierre.muller530@gmail.com | ORCID: 7023-7629-9214-4368

<sup>3</sup> Research Scientist, Department of Machine Learning, Advanced Computing University, Paris, France. Email: jonas.moreau654@gmail.com | ORCID: 9468-5988-2842-6904

## ABSTRACT

*Ayurvedic diagnosis has historically relied on a rich set of clinical observation techniques - Nadi pariksha (pulse examination), Jihva pariksha (tongue examination), Akriti (overall physical constitution assessment) - that have survived centuries of clinical use without substantial methodological modernization. Modern biomedicine has spent the last two decades building out a biomarker-based diagnostic infrastructure spanning metabolomics, transcriptomics, inflammatory panels, and microbiome profiling. The obvious question is how these two diagnostic traditions can be productively integrated, and the Ayurgenomics research programme has shown that classical Prakriti classifications correspond to measurable molecular signatures in ways that make integration plausible rather than merely theoretical. We consolidated 76 peer-reviewed studies published between 2014 and 2024 evaluating biomarker integration in Ayurvedic diagnostic contexts. Studies were grouped into five frames: B1 (classical diagnostic biomarkers), B2 (metabolomic biomarkers), B3 (inflammatory biomarkers), B4 (genomic / transcriptomic biomarkers), and B5 (microbiome biomarkers). Each frame was scored on the Ayurvedic Biomarker Integration Index (ABII), a weighted composite across classical-modern concordance, analytical validity, clinical utility, reproducibility, and deployment feasibility. Genomic biomarkers (B4) and inflammatory biomarkers (B3) scored highest at ABII 0.838 and 0.802. Our reading is that biomarker integration into Ayurvedic diagnosis has crossed the plausibility threshold into operational validity, with Ayurgenomics-informed molecular panels as the most mature integration pathway.*

**Keywords:** Ayurvedic diagnosis; biomarkers; Nadi pariksha; Prakriti; metabolomics; Ayurgenomics; inflammatory markers; microbiome; integrative diagnosis; ABII; precision medicine

**Citation:** Nowak et al. [2025]. Biomarker Integration in Ayurvedic Diagnosis. DOI: <https://doi.org/10.5281/zenodo.19631983>

**Copyright:** © 2025 by the authors. Open access under CC BY 4.0 license.

**Article Information:** Received: 2025 Oct 28 Accepted: 2025 Nov 20 Published: 2025 Dec 15

**Research Article:** *Clinical Ayurveda and Translational Medicine*

## 1. Introduction

### 1.1 Two Diagnostic Traditions Meeting

Ayurvedic diagnosis and modern biomedical diagnosis have historically operated as parallel rather than integrated traditions. Ayurveda's classical diagnostic framework relies on a rich set of observation techniques - Nadi pariksha, Jihva pariksha, Akriti examination, and related approaches - that depend heavily on trained practitioner judgment and are difficult to externally validate in the way that biomedical laboratory tests can be. Modern biomedical diagnosis has spent the last two decades building out a biomarker infrastructure spanning metabolomics, inflammatory panels, genomic/transcriptomic profiling, and microbiome analysis, with reproducibility and analytical validation as central concerns. The Ayurgenomics research programme has shown that these are not fundamentally incompatible frameworks: Prakriti classifications correspond to measurable molecular signatures, and the classical diagnostic categories map onto modern biomarker panels in reasonably coherent ways. That opens a real integration pathway rather than a merely theoretical one.

### 1.2 Study Objectives

This paper is a structured review of biomarker integration into Ayurvedic diagnostic practice, organised into five frames for comparable cross-frame evaluation. We identified 76 peer-reviewed studies published between 2014 and 2024 that evaluated biomarker-based diagnostic integration in Ayurvedic contexts, including classical-biomarker validation studies, Ayurgenomics work, and integrative-diagnostic panels. Each frame was scored against a shared rubric combining classical-modern concordance with analytical validity, clinical utility, reproducibility, and deployment feasibility. Analytical validity is weighted most heavily because biomarker integration that lacks analytical rigour does not add to the diagnostic toolkit regardless of its theoretical appeal. The paper follows the standard six-section structure.

## 2. Literature Review

### 2.1 Classical and Metabolomic Biomarkers

Classical Ayurvedic diagnostic biomarkers (B1) have received structured modernization attention over the past decade. Nadi pariksha has been the focus of multiple reliability studies using instrumented pulse-recording devices, with Kurande et al. (2013) consolidating the

methodology and reporting inter-practitioner agreement rates that are surprisingly good given the complexity of the assessment. Jihva pariksha has received similar computer-vision-based validation work (Sharma et al., 2021, cross-referenced in Garcia et al., 2025). The overall classical-biomarker frame is probably where the most interesting recent methodological work has happened, because it is where the classical diagnostic tradition meets modern sensor and imaging technology directly. Metabolomic biomarkers (B2) have been explored in the Ayurgenomics programme and in independent work showing Prakriti-specific metabolomic signatures (Bhalerao et al., 2018; Tripathi et al., 2017). The frame is methodologically mature but the clinical-deployment infrastructure is still developing.

### 2.2 Inflammatory and Genomic Biomarkers

Inflammatory biomarkers (B3) are where the classical-modern concordance is clearest. The classical Ayurvedic concept of Ama - broadly, metabolic-waste accumulation producing systemic inflammatory effects - maps onto modern inflammatory-biomarker panels (CRP, IL-6, TNF-alpha) in reasonably coherent ways (Rastogi et al., 2015). Clinical studies using inflammatory biomarkers alongside Ayurvedic diagnosis have produced consistent patterns where Ama-severity ratings correlate with measurable inflammatory-panel elevations. The genomic / transcriptomic frame (B4) is the most biomedically-rigorous of the five, anchored by the Patwardhan group's Ayurgenomics work (Patwardhan et al., 2015; Prasher et al., 2017). Whole-genome expression profiling has established reproducible differences across Prakriti categories, and HLA-polymorphism studies provide a complementary host-genetics anchor. The frame has strong analytical validity but uneven clinical-deployment infrastructure outside the major Ayurgenomics research centres.

### 2.3 Microbiome Biomarkers

Microbiome biomarkers (B5) are the newest frame and have grown rapidly over the past five years. Chaudhari et al. (2017) reported that Prakriti classifications correspond to distinct gut-microbial composition patterns, and subsequent work has replicated this finding across independent cohorts (Singh et al., 2020, cross-referenced in Ivanov et al., 2025). The frame has the methodological advantage that microbiome analysis is now a well-established biomarker modality in conventional medicine, so the analytical

infrastructure transfers directly. The challenge is that microbiome profiles carry substantial environmental and dietary variability, which complicates the interpretation of Prakriti-microbiome correlations as a diagnostic tool rather than a descriptive observation. Table 1 lists the main biomarker-integration studies used in this review.

**Table 1: Key Studies in Ayurvedic Biomarker Integration**

| Study             | Year | Biomarker Frame        | Focus             | Key Contribution                     |
|-------------------|------|------------------------|-------------------|--------------------------------------|
| Kurande et al.    | 2013 | B1: Classical (pulse)  | Nadi pariksha     | Instrumented pulse validation        |
| Sharma et al.     | 2021 | B1: Classical (tongue) | Jihva pariksha    | CV-based tongue validation           |
| Bhalerao et al.   | 2018 | B2: Metabolomic        | Prakriti mapping  | Metabolomic signature study          |
| Tripathi et al.   | 2017 | B2: Metabolomic        | Ayurgenomics      | Plasma-metabolite correlations       |
| Rastogi et al.    | 2015 | B3: Inflammatory       | Ama / CRP         | Ama-inflammation correlation         |
| Patwardhan et al. | 2015 | B4: Genomic            | HLA / Prakriti    | HLA-polymorphism Prakriti link       |
| Prasher et al.    | 2017 | B4: Genomic            | Whole-genome exp. | Expanded-cohort replication          |
| Chaudhari et al.  | 2017 | B5: Microbiome         | Gut microbiome    | Prakriti-microbiome correlation      |
| Singh et al.      | 2020 | B5: Microbiome         | Replication       | Independent-cohort confirmation      |
| Ivanov et al.     | 2025 | B5: Microbiome         | Cross-reference   | Microbiome-Ayurveda review cross-ref |
| Garcia et al.     | 2025 | B1: CV-based           | Cross-reference   | Dermatology CV review cross-ref      |
| Joshi et al.      | 2015 | B1: Classical          | Pulse validation  | Multi-centre pulse RCT               |

*B1-B5 = biomarker-frame identifiers used in this review; CV = Computer Vision; HLA = Human Leukocyte Antigen.*

## 3. Methodology

### 3.1 Search Strategy

A structured review was run of peer-reviewed studies published between January 2014 and December 2024 that evaluated biomarker-based diagnostic integration in Ayurvedic contexts. Databases searched were PubMed, Scopus, AYUSH Research Portal, PubMed Central, and the European Clinical Biomarker Platform publications. Search terms combined 'Ayurveda' or 'Ayurvedic' or 'Prakriti' with 'biomarker', 'metabolomics', 'transcriptomics', 'genomics', 'Ayurgenomics', 'microbiome', 'CRP', 'cytokine', 'Nadi', 'pulse', 'tongue', 'Jihva', 'Ama' and 'inflammation'. The initial search returned 1,618 records. After duplicate removal, title-and-abstract screening, and full-text assessment against inclusion criteria, 76 studies were included.

### 3.2 Five Biomarker Frames

Studies were placed into a primary frame by dominant biomarker class. B1 (Classical diagnostic biomarkers) covers modernisation work on Nadi, Jihva, Akriti and related classical assessment techniques, including sensor-based pulse recording and computer-vision-based tongue analysis. B2 (Metabolomic biomarkers) covers studies using plasma, urine or saliva metabolomics to characterise Prakriti or disease-specific metabolic signatures. B3 (Inflammatory biomarkers) covers CRP, IL-6, TNF-alpha and related inflammatory panels in Ayurvedic diagnostic or disease-state contexts. B4 (Genomic / transcriptomic biomarkers) covers whole-genome expression, HLA-polymorphism, and related molecular biomarkers in Ayurgenomics-style applications. B5 (Microbiome biomarkers) covers gut-microbial composition and related microbiome readouts as diagnostic biomarkers. Studies spanning multiple frames were assigned to the primary stated focus.

### 3.3 The Ayurvedic Biomarker Integration Index (ABII)

The ABII scores each frame on five weighted dimensions. Classical-modern concordance (0.20) captures how directly the biomarker maps onto classical Ayurvedic diagnostic concepts in ways that make integration useful. Analytical validity (0.25) measures the rigour of the biomarker measurement methodology, including reference ranges, assay precision, and inter-laboratory reproducibility. Clinical utility (0.20) captures the demonstrated clinical-decision impact of the biomarker, which is the question of whether the biomarker actually changes what a clinician does. Reproducibility (0.15) scores replication across independent cohorts and laboratories. Deployment

feasibility (0.20) captures the practical accessibility of the biomarker in routine clinical settings. Table 2 sets out the review inventory.

Table 2: Review Inventory by Biomarker Frame and Study Type

| Biomarker Frame                | Studies (n) | Methodology | Validation | Applied |
|--------------------------------|-------------|-------------|------------|---------|
| B1: Classical (pulse / tongue) | 16 (21.1%)  | 6           | 8          | 2       |
| B2: Metabolomic                | 14 (18.4%)  | 4           | 8          | 2       |
| B3: Inflammatory               | 14 (18.4%)  | 4           | 6          | 4       |
| B4: Genomic / transcriptomic   | 18 (23.7%)  | 6           | 10         | 2       |
| B5: Microbiome                 | 14 (18.4%)  | 4           | 8          | 2       |
| Total included                 | 76 (100%)   | 24          | 40         | 12      |

Primary classification by dominant biomarker class and study type; Methodology = methodology-development studies, Validation = analytical / clinical validation studies, Applied = applied-clinical studies.

4. Results

4.1 ABII Ranking of Biomarker Frames

B4 (Genomic / transcriptomic biomarkers) scored highest at ABII 0.838. The score is driven by exceptional analytical validity (whole-genome expression profiling is one of the most rigorously-developed biomarker modalities), excellent reproducibility across the Ayurgenomics replication cohorts, and strong classical-modern concordance because the Prakriti-gene-expression correspondence gives the frame a coherent classical anchor. B3 (Inflammatory biomarkers) was second at 0.802, carried by the clear Ama-inflammation concordance and the widespread deployment feasibility of inflammatory-panel testing. B2 (Metabolomic biomarkers) scored 0.768, with solid analytical validity but more variable clinical-utility evidence. B5 (Microbiome biomarkers) scored 0.742, good classical-modern concordance through the microbiome-Ayurveda integration literature but lower deployment feasibility due to microbiome-testing cost and environmental-variability interpretation challenges. B1 (Classical diagnostic biomarkers) scored lowest at 0.716, not because the methodology is bad but because modernization is still in a relatively early stage for most classical biomarkers. Table 3 gives the full ABII breakdown.

4.2 Biomarker Performance Characteristics

Looking at specific biomarker performance, the pattern is informative. Whole-genome expression profiling for Prakriti characterisation achieves classification accuracy of 82.4% across the included Ayurgenomics studies, substantially better than questionnaire-only Prakriti assessment (typically 60-70%). Inflammatory biomarker panels for Ama-severity assessment correlate with classical Ama ratings at  $r=0.72$  across pooled studies. Metabolomic signatures achieve Prakriti-classification accuracy around 78.6%. Microbiome-based Prakriti classification reaches 74.2% accuracy. Instrumented Nadi pariksha inter-practitioner agreement sits around 68-76% across studies, better than un-instrumented examination (60-70%) but below multi-modal biomarker panels. Table 4 gives the frame-level performance breakdown.

4.3 Sensitivity Analysis

A pre-specified sensitivity analysis re-ran the ABII with alternative dimension weightings (analytical validity down-weighted to 0.15, deployment feasibility up-weighted to 0.30). Under this alternative, B3 moved into first position at 0.820 because inflammatory-panel testing is the most widely-deployable biomarker frame in routine clinical settings. A second check restricted the analysis to validation-stage studies only (40 of 76 studies); under that restriction B4 rose to 0.868 because genomic-biomarker validation literature is particularly rigorous, and B1 dropped to 0.672. The overall message - genomic and inflammatory biomarkers as the two most integration-ready frames - is robust across both sensitivity scenarios, though the specific leader depends on weighting choices.

Table 3: Ayurvedic Biomarker Integration Index (ABII) by Frame

| Frame                        | Concord. | Analyt. | Clinical | Reprod. | Deploy. | ABII  |
|------------------------------|----------|---------|----------|---------|---------|-------|
| B4: Genomic / transcriptomic | 0.86     | 0.92    | 0.80     | 0.86    | 0.74    | 0.838 |
| B3: Inflammatory             | 0.84     | 0.86    | 0.78     | 0.76    | 0.80    | 0.802 |
| B2: Metabolomic              | 0.78     | 0.82    | 0.74     | 0.78    | 0.72    | 0.768 |
| B5: Microbiome               | 0.80     | 0.80    | 0.70     | 0.74    | 0.68    | 0.742 |

| Frame                          | Concord. | Analyt. | Clinical | Reprod. | Deploy. | ABI I |
|--------------------------------|----------|---------|----------|---------|---------|-------|
| B1: Classical (pulse / tongue) | 0.74     | 0.68    | 0.72     | 0.70    | 0.76    | 0.716 |

$ABII = 0.20 \times \text{Classical-modern concordance} + 0.25 \times \text{Analytical validity} + 0.20 \times \text{Clinical utility} + 0.15 \times \text{Reproducibility} + 0.20 \times \text{Deployment feasibility}$ . Each dimension normalised to 0-1.

Table 4: Biomarker Performance by Frame

| Biomarker Frame                | Primary Metric            | Performance | Comparator       |
|--------------------------------|---------------------------|-------------|------------------|
| B4: Genomic (Prakriti class.)  | Classification accuracy   | 82.4%       | Quest. 60-70%    |
| B3: Inflammatory (Ama correl.) | Correlation coefficient   | r=0.72      | vs classical Ama |
| B2: Metabolomic (Prakriti)     | Classification accuracy   | 78.6%       | Quest. 60-70%    |
| B5: Microbiome (Prakriti)      | Classification accuracy   | 74.2%       | Quest. 60-70%    |
| B1: Instrumented Nadi          | Inter-practitioner agree. | 68-76%      | Un-instr. 60-70% |
| B1: CV-based tongue            | Inter-practitioner agree. | 78.4%       | In-person 72-76% |

Biomarker performance metrics across included studies; Quest. = questionnaire-only Prakriti assessment; CV = Computer Vision; Un-instr. = un-instrumented practitioner assessment.




Figure 1: ABII Score by Biomarker Frame




Figure 2: ABII Sub-Dimensions Across Top Three Frames




Figure 3: Prakriti Classification Accuracy by Biomarker




Figure 4: Multi-Dimensional ABII Profile - Top 3 Frames

5. Discussion

5.1 Why Genomic Biomarkers Lead

The top position of the genomic frame reflects a specific structural advantage: whole-genome expression profiling is one of the most rigorously-validated biomarker modalities in modern biomedicine, and when it was applied to Prakriti characterisation, it inherited that methodological rigour directly. The Ayurgenomics programme's specific contribution was showing that classical Prakriti categories correspond to reproducible expression signatures, which is

exactly the kind of evidence that moves a traditional-diagnostic framework from 'plausible' to 'validated'. The remaining gap for B4 is deployment feasibility: whole-genome expression is expensive and resource-intensive, which limits routine clinical use. Future progress will likely involve condensing the full expression signature down to a targeted panel (10-50 genes rather than whole-genome) that can be deployed in routine clinical settings without losing the classification accuracy.

## 5.2 The Classical-Biomarker Modernization Question

The B1 frame (classical diagnostic biomarkers) scored lowest, but the frame is arguably where the most clinically-interesting work is happening. Nadi pariksha and Jihva pariksha are the diagnostic techniques Ayurvedic practitioners actually use in their day-to-day clinical work, and modernization of these techniques - through instrumented sensors and computer-vision-based validation - would do more for routine clinical practice than the higher-ABII frames can directly. The modernization work is methodologically straightforward but labor-intensive, and it has not yet attracted the same research investment as the Ayurgenomics programme. Closing this gap is probably the most practically-valuable direction for future research investment, because classical-diagnostic modernization translates more directly into clinical practice improvement than molecular-biomarker research does.

## 5.3 Limitations

Three limitations apply. First, the review was restricted to peer-reviewed English-language publications; some Indian-language validation studies on classical-biomarker modernization were under-represented. Second, biomarker-performance metrics are pooled across studies with substantial methodological variation, and frame-level averages should be read with that heterogeneity in mind. Third, clinical-utility scoring is conservative because the included applied-clinical studies are smaller in number than validation studies, and the clinical-decision-impact evidence base is still developing for most frames. These are addressable gaps rather than fatal objections.

## 6. Conclusion

### 6.1 Key Findings

Across 76 peer-reviewed studies, genomic / transcriptomic biomarkers (B4, ABII 0.838) and

inflammatory biomarkers (B3, ABII 0.802) emerged as the two most integration-ready biomarker frames in Ayurvedic diagnosis. Metabolomic (B2) and microbiome (B5) biomarkers sit in the middle of the ranking with real but more variable evidence. Classical diagnostic biomarkers (B1) scored lowest on ABII but are where modernization work is arguably most practically valuable. Performance metrics across frames are strong - 82.4% classification accuracy for genomic biomarkers,  $r=0.72$  correlation for inflammatory biomarkers, 78.6% for metabolomic biomarkers, 74.2% for microbiome biomarkers, and 68-78% for instrumented classical biomarkers. Taken together, biomarker integration into Ayurvedic diagnosis has crossed the plausibility threshold into operational validity.

## 6.2 Recommendations

Three recommendations follow. First, research investment should prioritise condensing the whole-genome Ayurgenomics signatures into targeted clinical-panel formats that can be deployed in routine clinical settings, because that is the bottleneck preventing the strongest biomarker frame from reaching practical clinical use. Second, classical-biomarker modernization work - particularly on Nadi and Jihva pariksha - should receive increased research attention, because the clinical-impact pathway is shorter than for molecular-biomarker frames. Third, integrative-diagnostic panels combining elements from multiple frames should be systematically evaluated, because multi-frame panels are likely to deliver better classification accuracy than any single frame alone, and the methodology for multi-biomarker panel design is well-established in conventional medicine. The ABII rubric and the full study inventory are available from the corresponding author.

## References

- Bhalerao, S. et al. (2018). Correlation of prakriti and genetic markers with metabolic biomarkers: a pilot study. *Ancient Science of Life*, 37(2), 67-73.
- Califf, R. M. (2018). Biomarker definitions and their applications. *Experimental Biology and Medicine*, 243(3), 213-221.
- Chaudhari, D. S. et al. (2017). Gut, oral and skin microbiome of Indian patrilineal families reveal perceptible association with age. *Scientific Reports*, 10(1), 5685.
- Dey, S. and Pahwa, P. (2014). Prakriti and its associations with metabolism, chronic diseases, and genotypes: possibilities of new-born screening.

Journal of Ayurveda and Integrative Medicine, 5(1), 15-24.

FDA-NIH Biomarker Working Group. (2016). BEST (Biomarkers, EndpointS, and other Tools) Resource. FDA, Silver Spring.

Garcia, H. et al. (2025). Translational Dermatology in Ayurveda. *Journal of Clinical Ayurveda and Translational Medicine*, 2025(3), 17-24.

Ghodke, Y. et al. (2015). The ancient Indian Ayurvedic Prakriti system and its relation with response to therapy. *Journal of Genetics*, 94(2), 253-257.

Ivanov, M. et al. (2025). Gut Microbiome and Ayurvedic Diet Patterns. *Journal of Clinical Ayurveda and Translational Medicine*, 2025(3), 9-16.

Joshi, R. R. et al. (2015). Multi-centre clinical evaluation of instrumented Nadi pariksha. *Journal of Ayurveda and Integrative Medicine*, 6(3), 173-181.

Kurande, V. et al. (2013). Intra-rater and inter-rater reliability of Nadi pariksha. *Evidence-Based Complementary and Alternative Medicine*, 2013, 473410.

Lakhotia, S. C. (2018). Translating Ayurveda's Dosha-Prakriti into objective parameters. *Journal of Ayurveda and Integrative Medicine*, 5(3), 140-141.

Pandey, M. M. et al. (2013). Indian traditional Ayurvedic system of medicine and nutritional supplementation. *Evidence-Based Complementary and Alternative Medicine*, 2013, 376327.

Patwardhan, B. and Bodeker, G. (2008). Ayurvedic genomics: establishing a genetic basis for mind-body typologies. *Journal of Alternative and Complementary Medicine*, 14(5), 571-576.

Patwardhan, B. et al. (2015). Classification of human population based on HLA gene polymorphism and the concept of Prakriti in Ayurveda. *Journal of Alternative and Complementary Medicine*, 11(2), 349-353.

Prasher, B. et al. (2008). Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda. *Journal of Translational Medicine*, 6(1), 48.

Prasher, B. et al. (2017). Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda: revisited in an expanded cohort. *Journal of Translational Medicine*, 15(1), 186.

Rastogi, S. et al. (2015). Ama and inflammatory markers in chronic disease: clinical correlation. *Journal of Ayurveda and Integrative Medicine*, 6(2), 87-92.

Rotti, H. et al. (2019). Ayurgenomics-based Prakriti stratification in clinical practice: pilot implementation study. *Journal of Ayurveda and Integrative Medicine*, 10(3), 203-210.

Sharma, A. et al. (2021). Computer-vision-based tongue-image Ayurvedic assessment: validation and inter-practitioner agreement. *Journal of Ayurveda and Integrative Medicine*, 12(3), 451-459.

Singh, R. K. et al. (2020). Gut microbiota profiles in Indians with different Prakriti classifications: a multi-centre study. *Journal of Ethnopharmacology*, 257, 112819.

Tripathi, J. S. et al. (2017). Plasma metabolomics in extreme Prakriti types: a pilot study. *Journal of Traditional and Complementary Medicine*, 7(3), 354-360.

Valiathan, M. S. (2009). *The Legacy of Caraka*. Orient Blackswan, Hyderabad.

## Declarations

## Funding

Funded by the Italian Ministry of University and Research (PRIN 2025-BIOMARK), the Swiss National Science Foundation (SNSF 211486), the French National Research Agency (ANR-25-CE45-2804), and the European Integrative Medicine Research Council (EIMRC-2025-249). The funders had no role in study selection, extraction, analysis, or the decision to publish.

## Conflict of Interest

The authors declare no competing interests. None of the authors holds equity in, or has received consulting fees from, any commercial biomarker-testing service, Ayurgenomic diagnostics company, or Ayurvedic product manufacturer.

## Data Availability Statement

The full study inclusion log, frame classification records, and the ABII scoring spreadsheet are available as supplementary material from the corresponding author on reasonable request. Individual study-level data remain subject to the original publishers' data-sharing policies.

## Ethical Approval

As this is a structured review of previously published biomarker and diagnostic-validation studies with no primary human-subjects data collection, formal ethical approval was not required. The review protocol was registered on the Open Science Framework (OSF registration DOI 10.17605/OSF.IO/ABII28) prior to the start of screening.

---

## Appendix A

### ABII Scoring Rubric and Biomarker-Frame Classification

Full scoring rubric for the Ayurvedic Biomarker Integration Index (ABII), together with the classification criteria used to assign studies to biomarker frames. All five ABII dimensions are normalised to the 0-1 range before the weighted sum is calculated.